

Giovanni Tallini

Professore Ordinario della Scuola di Medicina e Chirurgia dell'Università di Bologna, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES).

Integrato come Dirigente Medico-Anatomia Patologica presso l'Azienda USL di Bologna. Regime di tempo pieno.

Responsabile dell'U.O. di Biologia Molecolare (S.S.) dell'Azienda USL di Bologna.

Indirizzo: Laboratorio di Patologia Molecolare-Anatomia Patologica, Istituto Oncologico "F.Addarii" - Policlinico S.Orsola

Attività Didattica: Anatomia Patologica e corso elettivo Esame Microscopico per il corso di Laurea in Medicina e Chirurgia; Scuole di specialità: Anatomia Patologica e altre scuole di specialità di area medica; membro del collegio docenti del Dottorato in Scienze Biomediche-Università di Bologna.

Attività assistenziale: refertazione esami citoistopatologici di routine presso l'Anatomia Patologica dell'Ospedale Maggiore dal 24/01/2017 (precedentemente presso l'Anatomia Patologica dell'Ospedale Bellaria). Direzione dell'U.O.S. di Biologia Molecolare dell'Azienda USL di Bologna che esegue analisi molecolari di routine per il dipartimento Oncologico dell'Azienda (dal 24 Luglio 2003).

Attività universitaria amministrativa: responsabile del corso integrato e della commissione d'esame in Anatomia Patologica (C.I. 14786) (Canale A), corso di Laurea in Medicina e Chirurgia; responsabile del corso integrato e della commissione d'esame, corso elettivo Esame Microscopico (C.I. 70795), corso di Laurea in Medicina e Chirurgia; coordinatore del IV anno (II semestre), corso di Laurea in Medicina e Chirurgia; membro della Commissione Tecnico Pedagogica, corso di Laurea in Medicina e Chirurgia (da Settembre 2014).

POSIZIONI PROFESSIONALI

Professore universitario di prima fascia
in Anatomia Patologica
presso l'Universita' di Bologna,
ordinario dal Novembre 2005;
attivita' assistenziale presso
l'Azienda USL di Bologna

Novembre 2002 – tutt'oggi

Associate Professor of Pathology
and Surgical Pathology Attending
Director Molecular Diagnostic Laboratory
Department of Pathology
Yale University School of Medicine
P.O. Box 208070, New Haven, CT06520-8070, USA

Luglio 1999 – Novembre 2002

Assistant Professor of Pathology
and Surgical Pathology Attending
Department of Pathology
Yale University School of Medicine
P.O. Box 208070, New Haven, CT06520-8070, USA

Luglio 1993 – Giugno 1999

FORMAZIONE**Specializzazione Post-Universitaria**

Oncologic Pathology Fellow
Department of Pathology
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, New York 10021, USA

Luglio 1991 – Giugno 1993

Chief Resident in Pathology
(Specializzando capo in Anatomia Patologica)
Department of Pathology
Yale University School of Medicine
New Haven, Connecticut, USA

Luglio 1990 – Giugno 1991

Resident in Pathology
(Specializzando in Anatomia Patologica)
Department of Pathology
Yale University School of Medicine
New Haven, Connecticut, USA

Luglio 1988 – Giugno 1990

Specializzando (Resident) Novembre 1985 – Giugno 1988
 Scuola di Specializzazione
 in Anatomia Patologica.
 Facolta' di Medicina e Chirurgia,
 Universita' Cattolica del Sacro Cuore,
 Policlinico "A. Gemelli", Roma.

Certificazioni Professionali

Certificato di formazione manageriale 17 Giugno 2016
 abilitante alle Funzioni di
 Direzione delle Strutture complesse
 (Regione Emilia-Romagna, DGR 318/2012
 e s.m. e DGR 1561/2013)

Diploma USA di specializzazione 28 Novembre 2001
 in Patologia Molecolare
 ("Molecular Genetic Pathology")

Diploma USA di specializzazione 3 Novembre, 1993
 in Anatomia Patologica
 ("American board of pathology")

Abilitazione all' esercizio della professione di Agosto 1990
 Medico Chirurgo negli Stati Uniti.
 Esame di licenza all' esercizio della professione
 ("FLEX - Federation Licencing EXamination")
 superato in Connecticut (USA)

Diploma di Specializzazione 11 Ottobre, 1989
 in Anatomia Patologica.
 Facolta' di Medicina e Chirurgia,
 Universita' Cattolica del Sacro Cuore,
 Policlinico "A. Gemelli", Roma.

Abilitazione all'esercizio della professione Sessione di Novembre 1985
 di Medico Chirurgo conseguita presso la
 Facolta' di Medicina e Chirurgia,
 Universita' Cattolica del Sacro Cuore,
 Policlinico "A. Gemelli", Roma.

Iscrizione all'ordine dei Medici Chirurghi dal 30/12/1985
 della Provincia di Roma

Carriera Scolastica ed Universitaria

Riconoscimento del diploma italiano di laurea negli Stati Uniti. Esame di equipollenza ("FMGEMS - Foreign Medical Graduate Examination in the Medical Sciences") superato con punteggio di 84 per la parte clinica e di 93 per la parte preclinica (il punteggio riflette una valutazione in percentile dei candidati).

Giugno 1987

Facolta' di Medicina e Chirurgia,
Universita' Cattolica del Sacro Cuore,
Policlinico "A. Gemelli", Roma.
Diploma di Laurea in Medicina e Chirurgia
conseguito il 23 luglio 1985
con il massimo dei voti (110/110) e lode.

1980-1985

Liceo Scientifico "S. Giovanni Evangelista",
Roma. Diploma di Maturita' scientifica
conseguito con il massimo dei voti (60/60).

1974 – 1979

ATTIVITA' SCIENTIFICA E DI RICERCA

L'attività del prof. Tallini svolge nel campo dell'anatomia patologica oncologica:

- Interesse scientifico: analisi dei meccanismi che controllano lo sviluppo e la progressione dei tumori, integrazione dell'analisi molecolare con dati patologici al fine di identificare marcatori molecolari clinicamente rilevanti, epidemiologia ed individuazione dei fattori di rischio per l'insorgenza delle neoplasie.
- Patologia di riferimento: neoplasie endocrine, neoplasie cerebrali, diagnostica molecolare dei tumori solidi, neoplasie di origine mesenchimale, patologia urogenitale.

Neoplasie tiroidee: analisi dei meccanismi che controllano lo sviluppo e la progressione dei tumori tiroidei. Membro del gruppo di lavoro che ha portato alla stesura del volume *Pathology and Genetics of Endocrine Organs* (2004) curato dalla Organizzazione Mondiale della Sanità; membro del gruppo di lavoro che ha portato alla stesura del volume e responsabile del capitolo 2.5-Poorly differentiated thyroid carcinoma per l'edizione del volume *WHO Classification of Tumours of Endocrine Organs* pubblicata nel 2017 [World Health Organization (WHO)/International Agency for Research on Cancer (IARC) book Tumors of Endocrine Organs (WHO/IARC Classification of Tumours series)]; è uno degli editori del volume *Tumors of the thyroid and Parathyroid Glands* curato dall'American Registry of Pathology (2014-quarta serie); è stato coautore del capitolo sulla ghiandola tiroidea nel libro *Rosai and Ackerman's Surgical Pathology* (testo base di anatomia patologica a vasta diffusione mondiale), nell'edizione del 2011 con il Prof. J.Rosai (decima edizione) e nell'edizione del 2018 con il Prof. T.J. Giordano (undicesima edizione).

Neoplasie solide di origine mesenchimale: studio dei processi tumorigenici. Il Prof. Tallini ha partecipato ai lavori del gruppo di studio internazionale Chromosome and Morphology (CHAMP) di cui è stato uno degli associati fin dalla sua costituzione nel 1994. Questo gruppo costituito da membri di prestigiose istituzioni europee ed americane è stato costituito con lo scopo di integrare risultati derivati dall'analisi molecolare e citogenetica di lesioni solide mesenchimali con dati patologici e clinici. L'attività scientifica del gruppo (1994-2002) ha fornito le basi per la classificazione delle lesioni dei tessuti molli oggi in vigore.

Patologia molecolare: l'applicazione a fini diagnostici di tecniche di biologia molecolare, con particolare riferimento all'utilizzo di metodiche innovative per l'analisi dei tumori solidi. È autore del capitolo Molecular diagnostic pathology of sarcomas nel volume *Molecular Pathology in Clinical Practice* testo di patologia molecolare a vasta diffusione (1st edition-2007, 2nd edition 2016, Ed. D.G.B. Leonard, Springer).

Neuropatologia Oncologica: studio e analisi molecolare delle neoplasie cerebrali.

Patologia urogenitale: analisi dei meccanismi molecolari che regolano la crescita e lo sviluppo dei tumori della prostata, con particolare riferimento al ruolo delle molecole di adesione.

PARTECIPAZIONE A ORGANIZZAZIONI E SOCIETA' SCIENTIFICHE O PROFESSIONALI

- Italian Thyroid Cancer Observatory (ITCO) foundation (member since 2017)
- Gruppo Italiano di Patologia Endocrina-SIAPEC (GIPE, Italian Endocrine Pathology Group, founding member and coordinator for thyroid pathology, 2014)
- Gruppo di studio Patologia Molecolare e Medicina Predittiva-SIAPEC (PMMP, Italian molecular pathology study group, founding member 2013)
- European Society of Pathology (2005)
- Società Italiana di Anatomia Patologica e Citologia (SIAPEC) (2004)
- International Society of Bone and Soft Tissue Pathology (Founding member, 2001)
- Endocrine Pathology Society (1998, president of the Society for the year 2015)
- Association for Molecular Pathology (USA) (1996-2003)
- Yale Cancer Center (USA) (1995-2002)
- Chromosome and Morphology (CHAMP) international collaborative study group (Founding member, 1994-2002)
- U.S. and Canadian Academy of Pathology (1993)
- Iscrizione all' Albo Professionale dell' Ordine dei Medici e Chirurghi dello stato del Connecticut (USA). Licenza # 031099 (1990-2003)
- Iscrizione all' Albo Professionale dell' Ordine dei Medici e Chirurghi dello stato di New York (USA). Licenza # P67568 (1992-1994)
- Memorial Hospital Alumni Society (USA) (dal 1993)
- American Medical Association (1988-2003)
- Iscrizione all'Albo Professionale dell' Ordine dei Medici e Chirurghi di Roma e provincia (dal 30 dicembre 1985, numero d'ordine 36525)

SEMINARI E CORSI SU INVITO PRESSO ISTITUZIONI ACCADEMICHE E PROFESSIONALI (Ultimi cinque anni)

- | | |
|---------------|---|
| 20/02/2014 | Session Chair for Anatomic Pathology, Scientific meeting of the Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES), Scuola di Medicina e Chirurgia, University of Bologna School of Medicine, Bologna, Italy. |
| 20/05/2014 | "BRAF analysis in thyroid cytology". Invited speaker, 2° Convegno inter-regionale of the Italian Association of Medical Endocrinology (Associazione Medici Endocrinologi-AME), Bologna, Italy. |
| 26-27/06/2014 | Faculty, "Thyroid Pathology for the Practicing Pathologist". Post-graduate Course of the Academie Internationale de Pathologie-Division Française, Paris, France. |
| 20-21/03/2015 | The Endocrine Pathology Society Conference for Re-examination of the Encapsulated Follicular Variant of Papillary Thyroid Cancer. Study group member. Boston, MA, USA. |
| 21/03/2015 | Endocrine Pathology Society symposium "Encapsulated follicular cell-derived tumors of the thyroid gland, a practical update", Moderator. United States and Canadian Academy of Pathology meeting. Boston, MA, USA. |

- 09/04/2015 Master I livello-Metodologie di Anatomia Patologica per lo studio di Biomarcatori Predittivi di risposta terapeutica. Invited speaker. "Tumor heterogeneity and neoplastic cell selection". University of Naples-Federico II School of Medicine, Napoli, Italy.
- 28/05/2015 "How histology and molecular biology may orient the surgeon", invited speaker. 102° National Congress of the Italian Society of Otorhinolaryngologic Surgery (SIO). Rome, Italy.
- 20/06/2015 "Organization of a molecular pathology Laboratory", invited speaker. Italian Group of Molecular Pathology and Predictive Medicine (PMMP)-National Meeting. Rome, Italy.
- 25-26/06/2015 Faculty, "Thyroid Pathology for the Practicing Pathologist".Post-graduate Course of the Academie Internationale de Pathologie-Division Française, Paris, France.
- 23/09/2015 "Nuove linee guida ATA per i tumori tiroidei", invited speaker. Meeting of the Italian Society of Pathology (SIAPEC), Milan, Italy.
- 13&14/11/2015 WHO classification of thyroid tumors: facts and problems". Invited speaker. 10th International Multidisciplinary Course on Thyroid Pathology and Cytology. Anatomia Patologica-Fondazione Policlinico Universitario A. Gemelli, Univeristà Cattolica del Sacro Cuore. Rome, Italy.
- 04/12/2015 "ATA guidelines and molecular testing", Invited speaker. Molecular Cytopathology Course, Naples, Italy.
- 10/03/2016 "Pathology and biology of thyroid oncocytic tumors", invited speaker. Department of Pathology and Laboratory Medicine, University of Pennsylvania-Perelman School of Medicine. Philadelphia, PA, USA.
- 26-28/04/2016 Consensus Meeting, WHO Classification of Tumours of Endocrine Organs (4th edition). Invited discussant; working group member- responsible author for chapter 2-5 Thyroid: Poorly differentiated carcinoma. Lyon, France.
- 12/03/2016 Endocrine Pathology Society symposium "Impact of Large-Scale Genomic Data on Practicing Endocrine Pathology", Moderator. United States and Canadian Academy of Pathology meeting. Seattle, WA, USA.
- 30-31/05/2016 "Raccomandazioni SIAPEC per l'organizzazione del laboratorio di diagnostica molecolare associato all'anatomia patologica", invited speaker (May 30). Session moderator (May 31). Italian Group of Molecular Pathology and Predictive Medicine (PMMP)-National Meeting.Bologna, Italy.
- 18/06/2016 "Variante follicolare incapsulata del carcinoma papillifero della tiroide: tumore benigno o tumore maligno?", invited speaker. Meeting of the Italian Thyroid Cancer Observatory (ITCO). Rome, Italy.
- 23-24/06/2016 Faculty, "Thyroid Pathology for the Practicing Pathologist".Post-graduate Course of the Academie Internationale de Pathologie-Division Française, Paris, France.
- 26/09/2016 "Update of WHO classification of thyroid and parathyroid tumors". Invited speaker, meeting of the European Society of Pathology, Cologne, Germany.
- 27/09/2016 "Molecular endocrine pathology going into practice". Working group short course chair, meeting of the European Society of Pathology, Cologne, Germany.
- 22/10/2016 "Frontiers in Diagnosis and Management", invited Discussant. Meeting of the Italian Thyroid Cancer Observatory (ITCO). Milan, Italy.
- 23/11/2016 "Novità Classificative in Patologia Endocrina: Tiroide-UMP e NIFTP", invited speaker. Meeting of the "Gruppoitaliano di PatologiaEndocrina (GIPE)" at the Italian Society of Pathology (SIAPEC) meeting, Genova, Italy.
- 24/11/2016 "Nell'era dell'NGS – la Tecnologia e le Linee Guida: Linee guida sull'utilizzo dell'NGS in Diagnostica e aspetti economici", invited speaker.

- Meeting of the Italian Group of Molecular Pathology and Predictive Medicine (PMMP) at the Italian Society of Pathology (SIAPEC) meeting, Genova, Italy.
- 09/03/2017 "Unraveling the enigma of Hurthle Cell Tumors of the Thyroid Gland: Pathology and More", invited speaker. Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston. Houston, TX, USA.
- 02/03/2017 "Unraveling the enigma of thyroid oncocytic tumors", Departmental Seminar Series, invited speaker. Department of Pathology, Anatomy and Cell Biology, Sidney Kimmel Medical College at Thomas Jefferson University. Philadelphia, PA; USA.
- 05-06/06/2017 "Contro l'analisi NGS: possiamo completamente sostituire l'attuale tecnologia (Against NGS analysis: can we completely replace current sequencing methods)?" Invited speaker and session moderator. Italian Group of Molecular Pathology and Predictive Medicine (PMMP)-National Meeting. Florence, Italy.
- 22-23/06/2017 Faculty, "Thyroid Pathology for the Practicing Pathologist". Post-graduate Course of the Academie Internationale de Pathologie-Division Française, Paris, France.
- 03/09/2017 "Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)". Invited speaker, meeting of the European Society of Pathology, Amsterdam, Netherlands.
- 27/09/2017 "Italian Oncologists Got Talent" Faculty, Jury member for the session: Pancreatic cancer strategies for the metastatic setting, from Journals to Bedside. Multidisciplinary Oncology meeting. Bologna, Italy.
- 06/10/2017 "Histologic and molecular classification of thyroid neoplasms", invited speaker. Thyroid UpToDate meeting, Association of Medical Endocrinology (Associazione Medici Endocrinologi-AME), Ariccia-Rome, Italy.
- 13/10/2017 "Novità classificative e linee guida in patologia tiroidea", invited speaker. Meeting of the "Gruppo italiano di Patologia Endocrina (GIPE)" at the Italian Society of Pathology (SIAPEC) meeting, Naples, Italy.
- 13/10/2017 "Esperienze nella diagnostica di tumori ghiandolari (tiroide-ipofisi)", invited speaker. Meeting of the Italian Group of Molecular Pathology and Predictive Medicine (PMMP) at the Italian Society of Pathology (SIAPEC) meeting, Naples, Italy.
- 11-12/11/2017 Minicourse "Thyroid tumor classification and 2017 AJCC (American Joint Committee on Cancer)". Invited speaker. 16th national congress of the Italian Association of Medical Endocrinology (Associazione Medici Endocrinologi-AME), Rome, Italy.
- 30/11/2017 Slide seminar – Thyroid histology, Faculty. 11th International Multidisciplinary Course on Thyroid Pathology and Cytology. Anatomia Patologica-Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore. Rome, Italy.
- 01/12/2017 "ATA Guidelines for the management of thyroid tumors", Invited speaker. 11th International Multidisciplinary Course on Thyroid Pathology and Cytology. Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore. Rome, Italy.
- 04/12/2017 Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels, Session Chair. Molecular Cytopathology Course, Naples, Italy.
- 02-03/02/2018 United Kingdom Endocrine Pathology Society/Royal College of Pathologists Endocrine Pathology Update Meeting. Faculty. London, UK.
- 02/02/2018 Mini Symposium: Thyroid & WHO Classification of Endocrine Tumours 2017: "Encapsulated follicular lesions and other entities in the new WHO

- Classification (2017)". Invited speaker. United Kingdom Endocrine Pathology Society/Royal College of Pathologists Endocrine Pathology Update Meeting. London, UK.
- 17/03/2018 "Poorly Differentiated Thyroid Carcinoma: revised definition, molecular profile and histotype-specific prognostic factors" Invited speaker, Endocrine Pathology Society symposium: Clinical impact of surgical pathology in endocrine tumors, United States and Canadian Academy of Pathology meeting, Vancouver, BC, Canada.
- 16-18/04/2018 "Diagnostic Thyroid Pathology and Cytopathology". Postgraduate course. Guest Faculty. Vincent Academy of Pathology-Department of Pathology, Ordensklinikum Linz, Hospital of the Sisters of Charity, Linz, Austria.
- 14-15/05/2018 "L'NGS ad alta processività in diagnostica: aspetti tecnici, vantaggi e criticità-Un percorso per la diagnostica su materiale congelato. (High throughput NGS: technical aspects, pros and cons-a pathway for fresh frozen tissue)", invited speaker and session moderator. Italian Group of Molecular Pathology and Predictive Medicine (PMMP)-National Meeting. Florence, Italy.
- 18/06/2016 "Headlines/Breaking news in thyroid pathology (news from the WHO and AJCC)-New directions in the management of thyroid nodules and carcinomas", invited speaker. Meeting of the Italian Thyroid Cancer Observatory (ITCO). Perugia, Italy.
- 21-22/06/2018 Faculty, "Thyroid Pathology for the Practicing Pathologist". Post-graduate Course of the Academie Internationale de Pathologie-Division Française, Paris, France.
- 30/06/2018 "Il nuovo volto della tiroide (The new face of the thyroid gland)", Session moderator. Meeting of the Italian Thyroid Cancer Observatory (ITCO). Bologna, Italy.
- 03/09/2018 "Next generation sequencing in pancreatic cancer cytology" SY-28 Cytopathology: Consistency and reproducibility of next-generation sequencing and other multigene mutational assays. Invited speaker, meeting of the European Society of Pathology, Bilbao, Spain.
- 24/09/2018 "The molecular pathology laboratory for the analysis of solid tumors in the era of next generation sequencing". Session-The harmonized roles of Biomedical Laboratory Scientists and Pathologists in modern predictive medicine. Invited speaker, 33rd World Congress of Biomedical Laboratory Science (IFBLS), Florence, Italy.
- 26/11/2018 "Molecular pathology of thyroid tumours of follicular cells: genetic alterations and their clinicopathological relevance", Invited speaker, Molecular Cytopathology Course, Naples, Italy.
- 27/11/2018 Guideline updates in modern cytopathology. Session Chair. Molecular Cytopathology Course, Naples, Italy.

DISTINZIONI, PREMI E RICONOSCIMENTI

- **Membro dell'International Collaboration on Cancer Reporting (ICCR)** (www.iccr-cancer.org) initiative for the harmonisation of cancer reporting for **Thyroid cancer - Endocrine datasets (2018)**
- **Coautore del capitolo sulla Ghiandola Tiroidea nel libro Rosai and Ackerman's Surgical Pathology** (testo base di anatomia patologica a vasta diffusione mondiale), nell'edizione del 2011 con il Prof. J. Rosai (decima edizione) e nell'edizione del 2018 con il Prof. T.J. Giordano (undicesima edizione).
- **Scientific Committee member of the Italian Thyroid Cancer Observatory (ITCO) foundation (2017).**
- **World Health Organization working group member for the book: WHO Classification of Tumours of Endocrine Organs. WHO/IARC Classification of Tumours (2017).**
- **Presidente della Endocrine Pathology Society, a companion society of the United States and Canadian Academy of Pathology-USCAP (2015).**
- **Co-editore del volume *Tumors of the thyroid and Parathyroid Glands* curato dall'American Registry of Pathology (2014-quarta serie)**
- **World Health Organization working group member for the book: Pathology and Genetics-Tumors of Endocrine Organs. WHO/IARC Classification of Tumours (2004).**
- **The Averill A. Liebow Award for Excellence in the Teaching of Pathology Residents, Yale University Medical School, New Haven, CT (1996-97).**
- **Formazione professionale con il Prof. Juan Rosai (1988-1993), prima come Resident in Pathology (Specializzando in Anatomia Patologica) presso il Department of Pathology della Yale University School of Medicine (New Haven - Connecticut, Luglio 1988 - Giugno 1991), poi come Oncologic Pathology Fellow presso il Department of Pathology del Memorial Sloan Kettering Cancer Center (New York, Luglio 1991 – Giugno 1993)**

PARTECIPAZIONE ALL' ATTIVITA' DI RIVISTE E SOCIETÀ SCIENTIFICHE***Editorial board appointments (past or present)***

Endocrine pathology, Journal of Thyroid Research, Case Reports in Oncological Medicine, Journal of Molecular Diagnostics, Tumori, Advances In Anatomic Pathology, Pathology, Pathologica.

Ad Hoc Reviewer

American Journal of Pathology, Laboratory Investigation, Nature Medicine, Nature Reviews Cancer, Journal of Clinical Endocrinology and Metabolism, Endocrine Related Cancer, Endocrine, Thyroid, Cancer, Clinical Cancer Research, Journal of Clinical Oncology, Human Pathology, Analytical Biochemistry, Nucleic Acid Research, Oncology Research, Cancer Investigation, British Journal of Cancer, In Vitro-Cellular

and Developmental Biology, Diagnostic Molecular Pathology, International Journal of Cancer, International Journal of Surgical Pathology, Journal of Clinical Pathology, Journal of Pathology, Oncogene, Virchows Archiv.

Ad Hoc Referee for scientific projects and academic institutions

AIRC-Associazione Italiana per la Ricerca sul Cancro; Dutch Cancer Society; Agenzia Nazionale di Valutazione del Sistema Universitario e della Ricerca del Ministero dell'Istruzione, dell'Università e della Ricerca (ANVUR - MIUR); commissario giudice in procedure valutative per concorsi di professore universitario di I e II fascia (sette concorsuale: 06/A4-Anatomia Patologica; settore scientifico-disciplinare MED08); componente della Commissione (in esecuzione di provvedimenti giurisdizionali) per l'attribuzione dell'Abilitazione Scientifica Nazionale alle funzioni di professore di I e di II fascia (MIUR, tornata Abilitazione Scientifica Nazionale 2012-2013 e 2016-2018).

PROGETTI DI RICERCA FINANZIATI (RESEARCH SUPPORT)**Progetto Ordinario di Ricerca Finalizzata 2014-2015 del Ministero della Salute (RF-2016-02364167)**

25/October/2018 – present

Performance evaluation of the ThyT-1 signature in predicting aggressiveness of well differentiated Thyroid cancers in a pre-operative setting (valutazione dell'efficacia della ThyT-1 signature nel predire pre-operatoriamente l'aggressività di carcinoma tiroidei ben differenziati) (G. Tallini, Research unit coordinator)

Progetto Ordinario di Ricerca Finalizzata 2011-2012 del Ministero della Salute (RF-2011-02350857)

23/October/2014 to 26/November/2018

Role of anoctamin-1 in iodide transport and implications for the efficacy of radioiodine-based cancer therapy (Ruolo dell'anoctamina-1 nel trasporto di ioduro e le sue conseguenze per l'efficienza della terapia dei tumori con radioioduro) (G. Tallini, P.I.)

Programma di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN)–MIUR (20093XZC57_003)

17/October/2011 to 17/October/2013

Molecular profile of aggressive forms of thyroid carcinoma: validation of genetic biomarkers with tissue microarrays and correlation with angiogenesis and clinico-pathologic features (Profilo molecolare delle forme aggressive di carcinoma tiroideo: validazione di marcatori genetici mediante tissue microarray e correlazione con le caratteristiche clinico patologiche ed angiogenesi) (G. Tallini, Research unit coordinator)

Programma di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN)–MIUR (20074ZW8LA)

22/September/2008 to 19/December/2010

Functional characterization of iodide transport and Sodium Iodide Symporter (NIS) expression in thyroidal and extrathyroidal tumors (Espressione del Sodium/Iodide Symporter (NIS) nei tumori tiroidei ed extratiroidei: correlazione con caratteristiche clinicopatologiche e molecolari) (G. Tallini, P.I.)

Associazione Italiana per la Ricerca sul Cancro (AIRC)-Grant Regionale

31/January/2005 to 31/January/2007

Functional Genomics of Thyroid Oncocytomas (Genomica funzionale degli oncocitomi tiroidei) (G. Tallini, P.I.)

Ricerca Fondamentale Orientata (RFO)– Università di Bologna –MIUR

08/July/2003 to 08/July/2018

Molecular biomarkers of solid tumors (Biomarcatori molecolari dei tumori solidi) (G. Tallini, P.I.)

Thyroid Research Advisory Council,**Knoll Pharmaceutical Company**

01/June/2000 to 31/May/2001

Quantitation of Tissue and Tumor Specific mRNA Markers in the Peripheral Blood of Patients with Thyroid Carcinoma (G. Tallini, P.I.)

Goal: To establish the clinical relevance of RT-PCR tests in the peripheral blood of patients with thyroid carcinoma and monitor response to therapy to determine the risk for disease progression.

RO1 CA62006

1/September/1995 to 30/June/2001 (1% effort)

NIH NCI

Hair Dye Use and Risk of Non-Hodgkin's Lymphoma (T. Zheng, P.I.)

Goal: A case-control study of hair dye use and the associated risk of non-Hodgkin's Lymphoma in women in Connecticut

RO1 DK 52670

1/September/1997 to 31/August/2001 (10% effort)

NIH NIDDK

Molecular Regulation of Prostate Growth by Integrins (L.R. Languino, P.I.)

Goals: To study the distribution of integrins and extracellular matrix proteins in normal and hyperplastic prostate tissues and their role in regulating prostate growth.

DAMD17-98-1-8506

1/July/1998 to 31/January/2003 (5% effort)

US Army IDEA Award

β_1 and β_3 Integrins in Prostate Cancer (L.R. Languino, P.I.)

Goals, Phase I: To demonstrate *in vivo* and *in vitro* a direct role for β_1 , β_3 integrins, and for the signaling molecules regulated by β_1 and β_3 integrins in prostate cancer cell functions. **Goal,**

Phase II: To study the effect of 1) β_{1c} on prostate cancer primary cell growth *in vitro* and tumor growth *in vivo* and 2) β_3 on prostate metastasis establishment and growth in SCID mice.

RO1 CA89720

1/March/2001 to 28/February/2006 (5% effort)

NIH NCI

Integrin Signaling Pathways in Prostate Cancer (L.R. Languino, P.I.)

Goals: To investigate the downstream pathways activated by $\beta_1\beta_3$ engagement by vitronectin or osteopontin by characterizing the role of PI 3-kinase and Src, and of FAK/PI 3-kinase or FAK/Src association in modulating migration of LNCaP, PC3 and primary prostate cancer cells.

2 P30-CA16359

1/July/1998 to 30/June/2003 (5% effort)

NIH NCI

Critical Technologies Shared Resources-Comprehensive Cancer Center Core Support Grant

Dr. Tallini is Supervising Director of the Critical Technologies Shared Resource. The major goals of this project are to provide support for the Cancer Center programs and Core Facilities.

PUBLICATIONS**Bibliometric indicators (Febbraio 2019)****H-index: 63 (Scopus)****Total citations: 13110 (Scopus)****Impact factor-total: 890,946****Original Articles**

1. Cocchia D, Lauriola L, Stolfi V, Tallini G, Michetti F. S-100 antigen labels neoplastic cells in Liposarcomas and cartilaginous tumors. *Virchows Archives (Anat Pathol)*. 1983;402:139-145.
2. Lauriola L, Michetti F, Stolfi V, Tallini G, Cocchia D. Detection by S-100 immunolabelling of interdigitating reticulum cells in human thymomas. *Virchows Archives (Cell Pathol)*. 1984;45:187-195.
3. Cocchia D, Lauriola L, Stolfi V, Tallini G, Michetti F. The S-100 antigen in non-neural tumors. *Protides of the Biological Fluids*. 1984;31:409-412.
4. Lauriola L, Tallini G, Sentinelli S, Massi G. Protein absorption by tubular mesonephric and metanephric structures in the human embryo: an immunohistochemical study. *Cell & Tissue Research*. 1986;246:77-80.
5. Lauriola L, Coli A, Cocchia D, Tallini G, Michetti F. Comparative study by S-100 and GFAP immunohistochemistry of glial cell population in the early stages of human spinal cord development. *Developmental Brain Research*. 1987;37:251-255.
6. Rotmensch S, Liberati M, Luo J-S, Tallini G, Mahoney M J, Hobbins J C. Prenatal Diagnosis of a fetus with terminal deletion of Chromosome 1 (q41). *Prenatal Diagnosis*. 1991;11:867-873.
7. Zullo S, Kennedy J L, Gelernter J, Polymeropoulos MH, Tallini G, Pakstis A J, Shapiro M B, Merrill C R, Kidd K K. Eliminating mitochondrial DNA competition for nuclear DNA primers. *PCR Methods and Applications*, 1993;3:39-45.
8. Tallini G, Erlandson R A, Brennan M F, Woodruff J M. Divergent myosarcomatous differentiation in retroperitoneal liposarcomas. *American Journal of Surgical Pathology*. 1993;17:546-556.
9. Tallini G, Buckley P J, West A B. Diagnosis of gastrointestinal T-cell lymphomas in routinely processed tissue. *Journal of Clinical Gastroenterology*. 1993;17:57-66.
10. Folli F, Solimena M, Cofield R, Austoni M, Tallini G, Fassetta G, Bates D, Cartledge N, Bottazzo G F, Piccolo G, De Camilli P. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. *New England Journal of Medicine*. 1993;328:546-551.

11. Tallini G, Ladanyi M, Rosai J, Jhanwar S C. Analysis of nuclear and mitochondrial DNA alterations in thyroid and renal oncocyctic tumors. *Cytogenetic & Cell Genetic*. 1994;66:253-259.
12. Tallini G, Parham D M, Dias P, Cordon-Cardo C, Houghton P J, Rosai J. Myogenic regulatory protein expression in adult soft tissue sarcomas. *American Journal of Pathology*. 1994;144:693-701.
13. Viglietto G, Chiappetta G, Martinez-Tello F J, Fukunaga F H, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A. Ret/PTC oncogene activation is an early event in thyroid carcinogenesis. *Oncogene*. 1995;11:1207-1210.
14. McNiff J, Cooper D, Howe G, Crotty PL, Tallini G, Crouch J, Eisen RN: Lymphomatoid granulomatosis of the skin and lung. An angiocentric T-cell-rich B-cell lymphoproliferative disorder. *Archives of Dermatology*. 1996;132:1464-1470.
15. Tallini G, Akerman M, Dal Cin P, DeWever I, Fletcher C D M, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Van Den Berghe H, Van De Ven W, Vanni R, Willen H. Combined morphologic and karyotypic study of 28 myxoid liposarcomas. Implications for a revised morphologic typing (a report from the CHAMP Group). *American Journal of Surgical Pathology*. 1996;20:1047-1055.
16. Rosai J, Akerman M, Dal Cin P, DeWever I, Fletcher C D M, Mandahl N, Mertens F, Mitelman F, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Van De Ven W, Vanni R, Willen H. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship of differential diagnosis with other adipose tissue tumors (A report of the CHAMP Study Group). *American Journal of Surgical Pathology*. 1996;20:1182-1189.
17. Mandahl N, Akerman M, Aman P, Dal Cin P, De Wever I, Fletcher C D M, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Van De Ven W, Vanni R, Willen H. Duplication of chromosome segment 12q15-24 is associated with atypical lipomatous tumors: a report of the CHAMP collaborative study group. *International Journal of Cancer*. 1996;67:632-635.
18. Salloum E, Cooper D L, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. *Journal of Clinical Oncology*. 1996;14:1943-1949.
19. Fornaro M, Tallini G, Bofetiado C J M, Bosari S, Languino L R. Down-regulation of β_1c integrin, an inhibitor of cell proliferation, in prostate carcinoma. *American Journal of Pathology*. 1996;149:765-773.
20. Rosini S, Caltagirone S, Tallini G, Lattanzio G, Demopoulos R, Piantelli M, Musiani P. Depletion of stromal and intraepithelial antigen-presenting cells in cervical neoplasia in Human Immunodeficiency Virus infection. *Human Pathology*. 1996;27:834-838.

21. Fletcher C D M, Akerman M, Dal Cin P, De Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Van De Ven W, Vanni R, Willen H. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the chromosomes and morphology (CHAMP) collaborative study group. *American Journal of Pathology*. 1996;148:623-630.
22. Brady M S, Perino G, Tallini G, Woodruff J M, Russo P, Brennan M F. Malignant mesenchymoma. *Cancer*. 1996;77:467-473.
23. Rhoden K J, Tallini G, Douglas J S. H^+ - K^+ ATPase inhibitors cause relaxation of guinea pig and human airway smooth muscle *in vitro*. *Journal of Pharmacology and Experimental Therapeutics*. 1996;276:897-903.
24. Sciot R, Akerman M, Dal Cin P, DeWever I, Fletcher CDM, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Tallini G, Van Den Berghe H, Vanni R, Willen H. Cytogenetic analysis of subcutaneous angioliipoma: further evidence supporting its difference from ordinary pure lipomas. A report from the CHAMP study group. *American Journal of Surgical Pathology*. 1997;21:441-444.
25. Zheng D-Q, Fornaro M, Bofetiado CJM, Tallini G, Bosari S, Languino LR: Modulation of cell proliferation by the integrin cytoplasmic domain. *Kidney International*. 1997;51:1434-1440.
26. Tallini G, Dal Cin P, Rhoden KJ, Chiappetta G, Manfioletti G, Giancotti V, Fusco A, Van den Berghe H, Sciot R: Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: Immunohistochemical reactivity correlates with karyotypic alterations. *American Journal of Pathology*. 1997;151:37-43.
27. Pinto A, Tallini G, Novak R W, Bowen T, Parham D M. Undifferentiated rhabdomyosarcoma with lymphoid phenotype expression. *Medical and Pediatric Oncology*. 1997;28:165-170.
28. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. *Clinical Cancer Research*. 1998;4:287-294.
29. Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, Costa J, Robbins R, Burrow GN, Rosai J. Detection of thyroglobulin, thyroid peroxidase and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. *Journal of Clinical Oncology*. 1998;16:1158-1166.
30. Stefanato CM, Tallini G, Crotty PL. Histologic and immunophenotypic features prior to transformation in patients with transformed cutaneous T-cell lymphoma: is CD25 expression in skin biopsy samples predictive of large cell transformation in cutaneous T-cell lymphoma? *American Journal of Dermatopathology*. 1998;20:1-6.

31. Willen H, Akerman M, Dal Cin P, DeWever I, Fletcher CDM, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciò R, Tallini G, Van Den Berghe H, Vanni R. Comparison of chromosomal pattern with clinical features in 165 lipomas. A report of the CHAMP study group. *Cancer Genetic and Cytogenetics*. 1998;102:46-49.
32. Mertens F, Fletcher CD, Dal Cin P, DeWever I, Mandahl N, Mitelman F, Rosai J, Rydholm A, Sciò R, Tallini G, Van den Berghe H, Vanni R, Willen H. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features. A report of the CHAMP study group. *Genes Chromosomes Cancer*. 1998;22:16-25.
33. Crotty PL, Smith BR, Tallini G. Morphologic, immunophenotypic and molecular evaluation of bone marrow involvement in non-Hodgkin's lymphoma. *Diagnostic Molecular Pathology*. 1998;7:90-95.
34. Fornaro M, Manzotti M, Tallini G, Slear AE, Bosari S, Ruoslahti E, Languino LR. β_{1c} integrin in epithelial cells correlates with a non proliferative phenotype: forced expression of β_{1c} inhibits prostate epithelial cell proliferation. *American Journal of Pathology*. 1998;153:1079-1087.
35. Chiappetta G, Tallini G, de Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V, Fusco A. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. *Cancer Research*. 1998;58:4193-4198.
36. Fornaro M, Tallini G, Zheng DQ, Flanagan WM, Manzotti M, Languino LR. p27^{Kip1} acts as a downstream effector of and is coexpressed with the β_{1c} integrin in prostatic adenocarcinoma. *Journal of Clinical Investigation*. 1999;103:321-329.
37. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via $\alpha v \beta 3$ integrin is modulated by a focal adhesion kinase pathway. *Cancer Research*. 1999;59:1655-1664.
38. Garcia-Rostan G, Tallini G, Herrero H, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. *Cancer Research*. 1999;59:1811-1815.
39. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML. Downregulation of p27^{Kip1} and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. *American Journal of Surgical Pathology*. 1999;23:678-685.
40. Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC. Frequent chromosomal DNA unbalance in thyroid oncocyctic (Hürthle cell) neoplasms detected by comparative genomic hybridization. *Laboratory Investigation*. 1999; 79:547-555.
41. Sciò R, Rosai J, Dal Cin P, de Wever I, Fletcher CD, Mandahl N, Mertens F, Mitelman F, Rydholm A, Tallini G, van den Berghe H, Vanni R, Willen H. Analysis of 35 cases of

- localized and diffuse tenosynovial giant cell tumor: a report from the Chromosomes and Morphology (CHAMP) study group. *Modern Pathology*. 1999;12:576-579.
42. Fletcher CD, Dal Cin P, de Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, van den Berghe H, Vanni R, Willen H. Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group. *American Journal of Pathology*. 1999;154:1841-1847.
 43. Thayu M, Tallini G, Glusac EJ, Kacinski BM, Wilson LD. Evaluation of T-cell receptor gene rearrangements in patients with recurrent patch/plaque (T2) CTCL (mycosis fungoides). *Yale Journal of Biology and Medicine*. 1999;72:365-375.
 44. Mandahl N, Fletcher CD, Dal Cin P, De Wever I, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willen H. Comparative cytogenetic study of spindle cell and pleomorphic leiomyosarcomas of soft tissues: a report from the CHAMP Study Group. *Cancer Genetic and Cytogenetic*. 2000;116:66-73.
 45. Pedeutour F, Quade BJ, Sornberger K, Tallini G, Ligon AH, Weremowicz S, Morton CC. Dysregulation of HMGIC in a uterine lipoleiomyoma with a complex rearrangement including chromosomes 7, 12, and 14. *Genes Chromosomes Cancer*. 2000;27:209-215.
 46. Tallini G, Vanni R, Manfioletti G, Kazmierczak B, Faa G, Pauwels P, Bullerdiek J, Giancotti V, Van Den Berghe H, Dal Cin P. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. *Laboratory Investigation*. 2000;80:359-369.
 47. De Wever I, Dal Cin P, Fletcher CD, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willen H. Cytogenetic, clinical, and morphologic correlations in 78 cases of fibromatosis: a report from the CHAMP Study Group. *CHromosomes And Morphology. Modern Pathology*. 2000;13:1080-1085.
 48. Vanni R, Fletcher CD, Sciot R, Dal Cin P, De Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Tallini G, Van Den Berghe H, Willen H. Cytogenetic evidence of clonality in cutaneous benign fibrous histiocytomas: a report of the CHAMP study group. *Histopathology*. 2000;37:212-217.
 49. Zheng DQ, Woodard AS, Tallini G, Languino LR. Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. *Journal of Biological Chemistry*. 2000;275:24565-24574.
 50. Dei Tos AP, Doglioni C, Piccinin S, Sciot R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher CD, Tallini G. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. *Journal of Pathology*. 2000;190:531-536.
 51. Mertens F, Dal Cin P, DeWever I, Fletcher CD, Mandahl N, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willen H. Cytogenetic characterization

- of peripheral nerve sheath tumours: a report of the CHAMP study group. *Journal of Pathology*. 2000;190:31-38.
52. Sciot R, Dorfman H, Brys P, Dal Cin P, De Wever I, Fletcher CD, Jonson K, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Samson I, Tallini G, Van den Berghe H, Vanni R, Willen H. Cytogenetic-morphologic correlations in aneurysmal bone cyst, giant cell tumor of bone and combined lesions. A report from the CHAMP study group. *Modern Pathology*. 2000;13:1206-1210.
 53. Dal Cin P, Sciot R, Brys P, De Wever I, Dorfman H, Fletcher CD, Jonson K, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Samson I, Tallini G, Van den Berghe H, Vanni R, Willen H. Recurrent chromosome aberrations in fibrous dysplasia of the bone: a report of the CHAMP study group. *Cancer Genetic and Cytogenetic*. 2000;122:30-32.
 54. Chiappetta G, Tallini G, De Biasio MC, Pentimalli F, de Nigris F, Losito S, Fedele M, Battista S, Verde P, Santoro M, Fusco A. FRA-1 expression in hyperplastic and neoplastic thyroid diseases. *Clinical Cancer Research*. 2000;6:4300-4306.
 55. Dillon DA, Johnson CC, Topazian MD, Tallini G, Rimm DL, Costa JC. The utility of K-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasms. *International Journal of Cancer*. 2000;6:294-301.
 56. Broberg K, Tallini G, Hoglund M, Lindstrand A, Toksvig-Larsen S, Mertens F. The tumor associated gene HMGIC is expressed in normal and osteoarthritis-affected synovia. *Modern Pathology*. 2001;14:311-317.
 57. Garcia-Rostan G, Camp RL, A Herrero A, Carcangiu ML, DL Rimm DL, Tallini G. β -catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression and *ctnmb1* exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. *American Journal of Pathology*. 2001;158:987-996.
 58. Kim SH, Cho NH, Tallini G, Dudas M, Lewis JJ, Cordon-Cardo C. Prognostic role of cyclin D1 in retroperitoneal sarcomas. *Cancer*. 2001;91:428-434.
 59. Nucci MR, Weremowicz S, Neskey DM, Sornberger K, Tallini G, Morton CC, Quade BJ. Chromosomal translocation t(8;12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva. *Genes Chromosomes Cancer*. 2001;32:172-176.
 60. Dumollard JM, Ranchere-Vince D, Burel F, Coindre JM, Tallini G, Ligon AH, Mayaud R, Turc-Carel C, Martin C, Mosnier JF, Pedeutour F. Spindle cell lipoma and 13q deletion: diagnostic utility of cytogenetic analysis. *Annales de pathologie*. 2001;21:303-310.
 61. Bellantone R, Lombardi CP, Bossola M, Ferrante A, Princi P, Boscherini M, Maussier L, Salvatori M, Rufini V, Reale F, Romano L, Tallini G, Zelano G, Pontecorvi A. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study. *Cancer*. 2001;92:2273-9.

62. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A, Tallini G. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. *Journal of Clinical Endocrinology and Metabolism*. 2002;87:370-379.
63. Tallini G, Dorfman H, Brys P, Dal Cin P, DeWever, Fletcher CDM, Jonson K, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Samson I, Sciot R, van den Berghe, Vanni R, Willen H. Correlation between clinicopathological features and karyotype in 100 cartilagenous and chordoid tumours . *Journal of Pathology*. 2002;196:194-203.
64. Crisi GM, Rettig Emanuel J, Johnson C, Crotty PL, Costa J, Tallini G. Semi-reannealing single stranded conformational polymorphism (SR-SSCP): a novel and effective tool for the diagnosis of T-cell clonality. *Diagnostic Molecular Pathology*. 2002;11:67-74.
65. Fusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder BK, Dillon DA, Giuliano A, Cirafici AM, Santoro M, Rosai J, Tallini G. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphologic evidence of papillary carcinoma: a search for the early precursors of papillary cancer. *American Journal of Pathology*. 2002;160:2157-2167.
66. Mertens F, Stromberg U, Mandahl N, Cin PD, De Wever I, Fletcher CD, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, Van Den Berghe H, Vanni R, Willen H. Prognostically important chromosomal aberrations in soft tissue sarcomas: a report of the Chromosomes and Morphology (CHAMP) Study Group. *Cancer Research*. 2002;62:3980-3984.
67. Castellone MD, Cirafici AM, De Vita G, De Falco V, Maloni L, Tallini G, Fagin JA, Fusco A, Melillo RM, Santoro M. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. *Oncogene*. 2003;22:246-255.
68. Morton LM, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang Y, Flynn S, Tallini G, Zhang B, Owens PH, Zheng T. Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women. *British Journal of Cancer*. 2003;89:2087-2092.
69. Morton LM, Holford TR, Leaderer B, Zhang Y, Zahm SH, Boyle P, Flynn S, Tallini G, Owens PH, Zhang B, Zheng T. Alcohol use and risk of non-Hodgkin's lymphoma among Connecticut women (United States). *Cancer Causes Control*. 2003;14:687-694.
70. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR. Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor- α -induced Apoptosis via the AKT/Survivin Pathway. *Journal of Biological Chemistry*. 2003;278:50402-50411.
71. Hui P, Howe JG, Crouch J, Nimmakayalu M, Qumsiyeh MB, Tallini G, Flynn SD, Smith BR. Real-time quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma: comparison with FISH and immunohistochemistry. *Leukemia&Lymphoma*. 2003;44:1385-1394.

72. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. *Journal of Clinical Oncology*. 2003;21:3226-3235.
73. Dettori T, Frau DV, Lai ML, Mariotti S, Uccheddu A, Daniele GM, Tallini G, Faa G, Vanni R. Aneuploidy in oncocytic lesions of the thyroid gland: diffuse accumulation of mitochondria within the cell is associated with trisomy 7 and progressive numerical chromosomal alterations. *Genes Chromosomes Cancer*. 2003;38:22-31.
74. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW 2nd, Tallini G, Kroll TG, Nikiforov YE. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. *Journal of Clinical Endocrinology and Metabolism*, 2003;88:2318-2326.
75. Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, Tong BC, Tallini G, Udelsman R, Califano JA, Ladenson PW, Sidransky D. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. *Cancer Research*. 2003;63:2316-2321.
76. Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. *American Journal of Pathology*. 2004;165:511-521.
77. Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Owens PH, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Zheng T. Blood transfusion and risk of non-Hodgkin's lymphoma in Connecticut women. *American Journal of Epidemiology*. 2004;160:325-330.
78. Li N, McNiff J, Hui P, Manfioletti G, Tallini G. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity. *American Journal of Dermatopathology*. 2004;26:267-272.
79. Foschini MP, Papotti M, Parmeggiani A, Tallini G, Castaldini L, Meringolo D, Eusebi V. Three-dimensional reconstruction of vessel distribution in benign and malignant lesions of thyroid. *Virchows Archives*. 2004;445:189-198.
80. Wreesmann VB, Siczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. *Cancer Research*. 2004;64:3780-3789.
81. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Owens PH, Zheng T. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. *Cancer Causes Control*. 2004;15:419-428.

82. Morton LM, Engels EA, Holford TR, Leaderer B, Zhang Y, Zahm SH, Boyle P, Zhang B, Flynn S, Tallini G, Owens PH, Zheng T. Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. *Cancer Epidemiology Biomarkers & Prevention*. 2004;13:425-430.
83. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D. BRAF T1796A transversion mutation in various thyroid neoplasms. *Journal of Clinical Endocrinology and Metabolism*. 2004;89:1365-1368.
84. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, Sidransky D. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. *Cancer Research*. 2004;64:1664-1668.
85. Zheng T, Holford TR, Leaderer B, Zhang Y, Zahm SH, Flynn S, Tallini G, Zhang B, Zhou K, Owens PH, Lan Q, Rothman N, Boyle P. Diet and Nutrient Intakes and Risk of Non-Hodgkin's Lymphoma in Connecticut Women. *American Journal of Epidemiology*. 2004;159:454-466.
86. Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Flynn S, Tallini G, Owens PH, Zheng T. Hair-coloring product use and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut. *American Journal of Epidemiology*. 2004;159:148-154.
87. Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang B, Zou K, Morton LM, Owens PH, Flynn S, Tallini G, Zheng T. Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut women. *American Journal of Epidemiology*. 2004;160:766-773.
88. Rhoden KJ, Johnson C, Brandao G, Howe JG, Smith BR, Tallini G. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. *Laboratory Investigation*. 2004;84:1557-1570.
89. Hui P, Li N, Johnson C, De Wever I, Sciort R, Manfioletti G, Tallini G. HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor. *Modern Pathology*. 2005;18:1519-1526.
90. Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC, Sukumar S, Sidransky D. Tumor-specific changes in mtDNA content in human cancer. *International Journal of Cancer*. 2005;116:920-924.
91. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufano AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. *Journal of Clinical Endocrinology and Metabolism*. 2005;90:6373-6379.
92. Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, Zitzelsberger H, Tallini G. RET/papillary thyroid cancer

- rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. *Journal of Clinical Endocrinology and Metabolism*. 2006;91:2414-2423.
93. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G, Rugolo M, Romeo G. Defective Oxidative Phosphorylation in Thyroid Oncocytic Carcinoma Is Associated with Pathogenic Mitochondrial DNA Mutations Affecting Complexes I and III. *Cancer Research*. 2006;66:6087-6096.
94. Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA Jr, Santoro A, Franklin WA, Varela-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. *Annals of Oncology*. 2006;17:1120-1127.
95. Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Saha A, Tuttle RM, Ghossein RA. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. *Cancer*. 2006;107:1255-1264.
96. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V, Xing M. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. *International Journal of Cancer*. 2006;119:2322-2329.
97. Bonora E, Evangelisti C, Bonichon F, Tallini G, Romeo G. Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. *British Journal of Cancer*. 2006;95:1529-1536.
98. Morandi L, Ferrari D, Lombardo C, Pession A, Tallini G. Monitoring HCV RNA viral load by locked nucleic acid molecular beacons real time PCR. *Journal of Virological Methods*. 2007;140:148-154.
99. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. *Clinical Cancer Research*. 2007;13:1161-1170.
100. Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crino L, Brandes AA. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). *British Journal of Cancer*. 2007;96:1047-1051.
101. Ghossein RA, Leboeuf R, Patel KN, Rivera M, Katabi N, Carlson DL, Tallini G, Saha A, Singh B, Tuttle RM. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. *Thyroid*. 2007;17:655-661.

102. Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, Rinaldi Ceroni A, Curcio F, Carelli V, Rugolo M, Tallini G, Romeo G. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. *Proceedings of the National Academy of Sciences USA*. 2007;104:9001-9006.
103. Floris G, Debiec-Rychter M, Wozniak A, Magrini E, Manfioletti G, De Wever I, Tallini G, Sciò R. Malignant Ectomesenchymoma: Genetic Profile Reflects Rhabdomyosarcomatous Differentiation. *Diagn Mol Pathol*. 2007;16:243-248.
104. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. *Oncogene*. 2007;26:7590-7595.
105. Frau DV, Lai ML, Caria P, Dettori T, Coni P, Faa G, Morandi L, Tallini G, Vanni R. Trisomy 17 as a Marker For A Subset of Noninvasive Thyroid Nodules With Focal Features of Papillary Carcinoma: Cytogenetic and Molecular Analysis of 62 Cases and Correlation with Histologic Findings. *J Clin Endocrinol Metab*. 2008;93:177-181.
106. Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. *Br J Cancer*. 2008;99:83-89.
107. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnoli F, Ermani M. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. *J Clin Oncol*. 2008;26:2192-2197.
108. Flavin R, Jackl G, Finn S, Smyth P, Ring M, O'Regan E, Cahill S, Unger K, Denning K, Li J, Aherne S, Tallini G, Gaffney E, O'Leary J, Zitzelsberger H, Sheils O. RET/PTC Rearrangement Occurring in Primary Peritoneal Carcinoma. *Int J Surg Pathol*. 2009;17:187-197.
109. Unger K, Wienberg J, Riches A, Hieber L, Walch A, Brown A, O'Brien PC, Briscoe C, Gray L, Rodriguez E, Jackl G, Knijnenburg J, Tallini G, Ferguson-Smith M, Zitzelsberger H. Novel gene rearrangements in transformed breast cells identified by high-resolution breakpoint analysis of chromosomal aberrations. *Endocr Relat Cancer*. 2010;17:87-98.
110. Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA, Santoro A. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. *Ann Oncol*. 2010;21:562-567.
111. Morandi L, Franceschi E, De Biase D, Marucci G, Tosoni A, Ermani M, Pession A, Tallini G, Brandes AA. Promoter methylation analysis of O6-methylguanine-DNA

- methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. *BMC Cancer*. 2010 Feb 18;10:48. pp1-12 PubMed PMID: 20167086; PubMed Central PMCID: PMC2843669.
112. Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, Pennisi LF, Morra I, Ciccarelli E, Melcarne A, Bartoletti-Stella A, Salfi N, Tallini G, Martinuzzi A, Carelli V, Attimonelli M, Rugolo M, Romeo G, Gasparre G. The genetic and metabolic signature of oncocyctic transformation implicates HIF1 {alpha} destabilization. *Hum Mol Genet*. 2010;19:1019-32.
113. Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J. Encapsulated Well-differentiated Follicular-patterned Thyroid Carcinomas Do Not Play a Significant Role in the Fatality Rates From Thyroid Carcinoma. *Am J Surg Pathol*. 2010;34:868-872.
114. Ragazzi M, de Biase D, Betts CM, Farnedi A, Ramadan SS, Tallini G, Reis-Filho JS, Eusebi V. Oncocyctic carcinoma of the breast: frequency, morphology and follow-up. *Hum Pathol*. 2011;42:166-175.
115. Geyer FC, de Biase D, Lambros MB, Ragazzi M, Lopez-Garcia MA, Natrajan R, Mackay A, Kurelac I, Gasparre G, Ashworth A, Eusebi V, Reis-Filho JS*, Tallini G*. Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology. *Breast Cancer Res Treat*. 2011;132:15-28.*Share senior authorship
116. Durante C*, Tallini G*, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S. BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. *Eur J Endocrinol*. 2011;165:455-463. * Share first authorship
117. Voce P, D'Agostino M, Moretti S, Sponziello M, Rhoden K, Calcinaro F, Tamburrano G, Tallini G, Puxeddu E, Filetti S, Russo D, Durante C. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors. *Oncol Rep*. 2011;26:1075-1080.
118. Morandi L, de Biase D, Visani M, Monzoni A, Tosi A, Brulatti M, Turchetti D, Baccarini P, Tallini G, Pession A. T([20]) repeat in the 3'-untranslated region of the MT1X gene: a marker with high sensitivity and specificity to detect microsatellite instability in colorectal cancer. *Int J Colorectal Dis*. *Int J Colorectal Dis*. 2012;27:647-656.
119. Morandi L, de Biase D, Visani M, Cesari V, De Maglio G, Pizzolitto S, Pession A, Tallini G. Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation. *PLoS One*. 2012;7(4):e36084.
120. Celano M, Sponziello M, Tallini G, Maggisano V, Bruno R, Dima M, Di Oto E, Redler A, Durante C, Sacco R, Filetti S, Russo D. Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations. *Endocrine*. 2013 Feb;43(1):147-53. doi: 10.1007/s12020-012-9747-3.

121. Altimari A, de Biase D, De Maglio G, Gruppioni E, Capizzi E, Degiovanni A, D'Errico A, Pession A, Pizzolitto S, Fiorentino M, Tallini G. 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. *Onco Targets Ther.* 2013 Aug 5;6:1057-64. doi: 10.2147/OTT.S42369. eCollection 2013.
122. Piana S*, Ragazzi M*, Tallini G*, de Biase D, Ciarrocchi A, Frasoldati A, Rosai J. Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: Report of 3 cases, with morphological and molecular analysis. *Hum Pathol.* 2013 Apr;44(4):556-65. doi: 10.1016/j.humpath.2012.06.019. Epub 2012 Oct 15.* Share first authorship
123. Kurelac I, Mackay A, Lambros MB, Di Cesare E, Cenacchi G, Ceccarelli C, Morra I, Melcarne A, Morandi L, Calabrese FM, Attimonelli M, Tallini G, Reis-Filho JS, Gasparre G. Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas. *Hum Mol Genet.* 2013 Jan 15;22(2):226-38. doi: 10.1093/hmg/ddr422.
124. Pradella LM, Lang M, Kurelac I, Mariani E, Guerra F, Zuntini R, Tallini G, MacKay A, Reis-Filho JS, Seri M, Turchetti D, Gasparre G. Where Birt-Hogg-Dubé meets Cowden syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours. *Eur J Hum Genet.* 2013 Oct;21(10):1169-72. doi:10.1038/ejhg.2013.8. Epub 2013 Feb 6.
125. Bernstein J, Virk RK, Hui P, Prasad A, Westra WH, Tallini G, Adeniran AJ, Udelsman R, Sasaki CT, Roman SA, Sosa JA, Prasad ML. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis. *Thyroid.* 2013 Dec;23(12):1525-31. doi: 10.1089/thy.2013.0154. Epub 2013 Sep 3.
126. de Biase D, Visani M, Malapelle U, Simonato F, Cesari V, Bellevicine C, Pession A, Troncone G, Fassina A, Tallini G. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). *PLoS One.* 2013 Dec 23;8(12):e83607. doi: 10.1371/journal.pone.0083607. eCollection 2013.
127. Marucci G, de Biase D, Visani M, Giulioni M, Martinoni M, Volpi L, Riguzzi P, Rubboli G, Michelucci R, Tallini G. Mutant BRAF in low-grade epilepsy-associated tumors and focal cortical dysplasia. *Ann Clin Transl Neurol.* 2014 Feb;1(2):130-4. doi: 10.1002/acn3.31. Epub 2014 Jan 9.
128. de Biase D, Visani M, Baccarini P, Polifemo AM, Maimone A, Fornelli A, Giuliani A, Zanini N, Fabbri C, Pession A, Tallini G. Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. *PLoS One.* 2014 Feb 4;9(2):e87651. doi: 10.1371/journal.pone.0087651. eCollection 2014.
129. Fiorino S, Bacchi-Reggiani L, Pontoriero L, Gallo C, Chili E, Masetti M, Zanini N, Grondona A, Silvestri T, Deleonardi G, Fornelli A, Bondi A, de Biase D, Baccarini P, Tallini G, Tropeano A, Quartuccio V, Cuppini A, Castellani G, Jovine E. Tensegrity model

- hypothesis: may this paradigm be useful to explain hepatic and pancreatic carcinogenesis in patients with persistent hepatitis B or hepatitis C virus infection? *JOP*. 2014 Mar 10;15(2):151-64. doi: 10.6092/1590-8577/2099.
130. Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. *J Clin Endocrinol Metab*. 2014 May;99(5):E832-40. doi: 10.1210/jc.2013-3351. Epub 2014 Feb 11.
131. de Biase D, Cesari V, Visani M, Casadei GP, Cremonini N, Gandolfi G, Sancisi V, Ragazzi M, Pession A, Ciarrocchi A, Tallini G. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. *J Clin Endocrinol Metab*. 2014 Aug;99(8):E1530-8. doi: 10.1210/jc.2013-4389. Epub 2014 Apr 29.
132. Iosco C, Cosentino C, Sirna L, Romano R, Cursano S, Mongia A, Pompeo G, di Bernardo J, Ceccarelli C, Tallini G, Rhoden KJ. Anoctamin 1 is apically expressed on thyroid follicular cells and contributes to ATP- and calcium-activated iodide efflux. *Cell Physiol Biochem*. 2014;34(3):966-80. doi: 10.1159/000366313. Epub 2014 Aug 27.
133. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Clifton-Bligh R, Tallini G, Holt EH, Sýkorová V. Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer. *J Clin Oncol*. 2015 Jan 1;33(1):42-50. doi: 10.1200/JCO.2014.56.8253. Epub 2014 Oct 20.
134. Malapelle U, Sgariglia R, De Stefano A, Bellevicine C, Vigliar E, de Biase D, Sepe R, Pallante P, Carlomagno C, Tallini G, Troncone G. KRAS Mutant Allele-Specific Imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. *J Clin Pathol*. 2015 Apr;68(4):265-9. doi: 10.1136/jclinpath-2014-202761. Epub 2015 Jan 21. PubMed PMID: 25609577.
135. Evangelisti C*, de Biase D, Kurelac I, Ceccarelli C, Prokisch H, Meitinger T, Caria P, Vanni R, Romeo G, Tallini G*, Gasparre G, Bonora E. A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors. *BMC Cancer*. 2015 Mar 21;15:157. doi: 10.1186/s12885-015-1122-3.
***corresponding authors**
136. Marucci G, Fabbri PV, Morandi L, De Biase D, Di Oto E, Tallini G, Sturiale C, Franceschi E, Frezza GP, Foschini MP. Pathological spectrum in recurrences of glioblastoma multiforme. *Pathologica*. 2015 Mar;107(1):1-8. PubMed PMID: 26591624.
137. Kurelac I, de Biase D, Calabrese C, Ceccarelli C, Ng CK, Lim R, MacKay A, Weigelt B, Porcelli AM, Reis-Filho JS, Tallini G*, Gasparre G*. High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis

- loci in the oncocytic variants. *Am J Cancer Res.* 2015 May 15;5(6):1954-71. eCollection 2015. PubMed PMID: 26269756; PubMed Central PMCID: PMC4529616. * Share senior authorship
138. Martinoni M, Marucci G, de Biase D, Rubboli G, Volpi L, Riguzzi P, Marliani F, Toni F, Naldi I, Bisulli F, Tinuper P, Michelucci R, Baruzzi A, Tallini G, Giulioni M. BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliomas. *J Clin Neurosci.* 2015 Aug;22(8):1250-3. doi: 10.1016/j.jocn.2015.02.016. Epub 2015 Apr 27. PubMed PMID: 25937573.
139. de Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei GP, Durante C, Costante G, Bruno R, Torlontano M, Paschke R, Filetti S, Piana S, Frasoldati A, Tallini G*, Ciarrocchi A*. TERT Promoter Mutations in Papillary Thyroid Microcarcinomas. *Thyroid.* 2015 Sep;25(9):1013-9. doi: 10.1089/thy.2015.0101. Epub 2015 Aug 5. PubMed PMID: 26148423. *corresponding authors
140. Tallini G*, de Biase D, Durante C, Acquaviva G, Bisceglia M, Bruno R, Bacchi Reggiani ML, Casadei GP, Costante G, Cremonini N, Lamartina L, Meringolo D, Nardi F, Pession A, Rhoden KJ, Ronga G, Torlontano M, Verrienti A, Visani M, Filetti S. BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. *Mod Pathol.* 2015 Oct;28(10):1343-59. doi: 10.1038/modpathol.2015.92. Epub 2015 Aug 14. PubMed PMID: 26271724. *corresponding author
141. Trisolini R, Cancellieri A, Tinelli C, de Biase D, Valentini I, Casadei G, Paioli D, Ferrari F, Gordini G, Patelli M, Tallini G. Randomized trial of endobronchial ultrasound-guided transbronchial needle aspiration with and without rapid on-site evaluation for lung cancer genotyping. *Chest.* 2015 Dec;148(6):1430-7. doi: 10.1378/chest.15-0583. PubMed PMID: 26158441.
142. Marucci G, de Biase D, Zoli M, Faustini-Fustini M, Bacci A, Pasquini E, Visani M, Mazzatenta D, Frank G, Tallini G. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells. *Pituitary.* 2015 Dec;18(6):905-11. doi: 10.1007/s11102-015-0669-y. Erratum in: *Pituitary.* 2016 Feb;19(1):113. PubMed PMID: 26156055.
143. Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, Al-Kuraya K, Fugazzola L, Colombo C, Kebebew E, Jarzab B, Czarniecka A, Bendlova B, Sykorova V, Sobrinho-Simões M, Soares P, Kee Shong Y, Yong Kim T, Cheng S, Asa SL, Viola D, Elisei R, Yip L, Mian C, Vianello F, Wang Y, Zhao S, Oler G, Cerutti JM, Puxeddu E, Qu S, Wei Q, Xu H, O'Neill CJ, Sywak MS, Clifton-Bligh R, Lam AK, Riesco-Eizaguirre G, Santisteban P, Yu H, Tallini G, Holt EH, Vasko V, Xing M. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. *J Clin Endocrinol Metab.* 2016 Jan;101(1):264-74. doi: 10.1210/jc.2015-2917. Epub 2015 Nov 3. PubMed PMID: 26529630; PubMed Central PMCID: PMC4701842.

144. Fiorino S, Visani M, Acquaviva G, Fornelli A, Masetti M, Cuppini A, Bacchi-Reggiani ML, Jovine E, Tallini G, Pession A, de Biase D. Search for HBV and HCV Genome in Cancer Cells of Pancreatic Tumors. *Pancreas*. 2016 Jan;45(1):e12-e14. PubMed PMID: 26658043.
145. Farina E, Monari F, Tallini G, Repaci A, Mazzarotto R, Giunchi F, Panzacchi R, Cammelli S, Padula GD, Deodato F, Pasquali R, Fanti S, Fiorentino M, Morganti AG. Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review. *Endocr Pathol*. 2016 Mar;27(1):55-64. doi: 10.1007/s12022-015-9410-7. PubMed PMID: 26662609.
146. Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. *Cancer*. 2016 Apr 1;122(7):1097-107. doi: 10.1002/cncr.29887. Epub 2016 Jan 19. PubMed PMID: 26784937.
147. de Biase D, de Luca C, Gagnano G, Visani M, Bellevicine C, Malapelle U, Tallini G, Troncone G. Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. *J Clin Pathol*. 2016 Apr 27. pii: jclinpath-2016-203696. doi: 10.1136/jclinpath-2016-203696. [Epub ahead of print] PubMed PMID: 27122185.
148. Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, Sponziello M, Damante G, Russo D, Durante C. Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. *Endocrine*. 2016 Jul;53(1):145-56. doi: 10.1007/s12020-015-0739-y. Epub 2015 Sep 14. PubMed PMID: 26370117.
149. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVoisi VA, Randolph GW, Ghossein RA. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. *JAMA Oncol*. 2016 Aug 1;2(8):1023-9. doi: 10.1001/jamaoncol.2016.0386. PubMed PMID: 27078145.
150. Maletta F, Massa F, Torregrossa L, Duregon E, Casadei GP, Basolo F, Tallini G, Volante M, Nikiforov YE, Papotti M. Cytological features of "non-invasive follicular thyroid neoplasm with papillary-like nuclear features" and their correlation with tumor histology. *Hum Pathol*. 2016 Aug;54:134-42. doi: 10.1016/j.humpath.2016.03.014. Epub 2016 Apr 13. PubMed PMID: 27085556.
151. Verrienti A*, Tallini G*, Colato C*, Boichard A, Checquolo S, Pecce V, Sponziello M, Rosignolo F, de Biase D, Rhoden K, Casadei GP, Russo D, Visani M, Acquaviva G, Ferdeghini M, Filetti S, Durante C. RET mutation and increased angiogenesis in medullary thyroid carcinomas. *Endocr Relat Cancer*. 2016 Aug; 23(8):665-76. doi: 10.1530/ERC-16-0132. Epub 2016 Jul 8. PubMed PMID: 27402614. *equal contributors to the work.
152. Zoli M, Sambati L, Milanese L, Foschi M, Faustini-Fustini M, Marucci G, de Biase D, Tallini G, Cecere A, Mignani F, Sturiale C, Frank G, Pasquini E, Cortelli P, Mazzatenta D, Provini F. Postoperative outcome of body coretemperature rhythm and sleep-wake cycle in

- third ventricle craniopharyngiomas. *Neurosurg Focus*. 2016 Dec;41(6):E12. PubMed PMID: 27903128.
153. Brandes AA, Franceschi E, Paccapelo A, Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza G, Silini EM, Sturiale C, Volpin L, Servadei F, Talacchi A, Fioravanti A, Pia Foschini M, Bartolini S, Pession A, Ermani M. Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. *Oncologist*. 2017 Apr;22(4):432-437. doi:10.1634/theoncologist.2016-0254. Epub 2017 Mar 8. PubMed PMID: 28275120; PubMedCentral PMCID: PMC5388380.
154. Xu B, Tallini G, Scognamiglio T, Roman BR, Tuttle RM, Ghossein RA. Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. *Thyroid*. 2017 Apr;27(4):512-517. doi: 10.1089/thy.2016.0649. Epub 2017 Feb 24. PubMed PMID: 28136139; PubMed Central PMCID: PMC5385447.
155. Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borgh S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellecine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. *Cancer*. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5. PubMed PMID: 28475299.
156. de Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, Paccapelo A, Cancellieri A, Trisolini R, Degli Esposti R, Bartolini S, Pession A, Tallini G*, Brandes AA*. The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. *PLoS One*. 2017 May 16;12(5):e0177822. doi: 10.1371/journal.pone.0177822. eCollection 2017. PubMed PMID: 28520821. *share senior authorship
157. Vornetti G, Marucci G, Zenesini C, de Biase D, Michelucci R, Tinuper P, Tallini G, Giulioni M. Relationship among clinical, pathological and bio-molecular features in low-grade epilepsy-associated neuroepithelial tumors. *J Clin Neurosci*. 2017 Oct;44:158-163. doi: 10.1016/j.jocn.2017.06.022. Epub 2017 Jun 30. PubMed PMID: 28673671.
158. Visani M, Acquaviva G, Marucci G, Paccapelo A, Mura A, Franceschi E, Grifoni D, Pession A, Tallini G*, Brandes AA, de Biase D. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. *J Neurooncol*. 2017 Nov;135(2):245-254. doi: 10.1007/s11060-017-2571-0. Epub 2017 Jul 26. PubMed PMID: 28748342. *corresponding author
159. Gandolfi G, Ragazzi M, de Biase D, Visani M, Zanetti E, Torricelli F, Sancisi V, Gugnoni M, Manzotti G, Braglia L, Cavuto S, Merlo DF, Tallini G, Frasoldati A, Piana S, Ciarrocchi A. Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely

- metastatic Papillary Thyroid Carcinomas. *Oncotarget*. 2017 Dec 1;9(2):1813-1825. doi: 10.18632/oncotarget.22805. eCollection 2018 Jan 5. PubMed PMID: 29416733; PubMed Central PMCID: PMC5788601.
160. Xu B, Farhat N, Barletta JA, Hung YP, Biase D, Casadei GP, Onenerk AM, Tuttle RM, Roman BR, Katabi N, Nosé V, Sadow P, Tallini G, Faquin WC, Ghossein R. Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category? *Endocrine*. 2018 Jan;59(1):143-150. doi: 10.1007/s12020-017-1484-1. Epub 2017 Dec 4. PubMed PMID: 29204912; PubMed Central PMCID: PMC5766404.
161. Masetti M, Acquaviva G, Visani M, Tallini G*, Fornelli A, Ragazzi M, Vasuri F, Grifoni D, Di Giacomo S, Fiorino S, Lombardi R, Tuminati D, Ravaioli M, Fabbri C, Bacchi-Reggiani ML, Pession A, Jovine E, de Biase D. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. *Cancer Biomark*. 2018 Feb 6;21(2):323-334. doi: 10.3233/CBM-170464. PubMed PMID: 29103024. *corresponding author
162. Zoli M, Milanese L, Bonfatti R, Faustini-Fustini M, Marucci G, Tallini G, Zenesini C, Sturiale C, Frank G, Pasquini E, Mazzatenta D. Clival chordomas: considerations after 16 years of endoscopic endonasal surgery. *J Neurosurg*. 2018 Feb;128(2):329-338. doi: 10.3171/2016.11.JNS162082. Epub 2017 Apr 14. PubMed PMID: 28409727.
163. Acquaviva G, Visani M, de Biase D, Marucci G, Franceschi E, Tosoni A, Brandes AA, Rhoden KJ, Pession A, Tallini G. Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1(105GGT)) in brain tumors of a cohort of Italian patients. *Sci Rep*. 2018 Mar 13;8(1):4459. doi: 10.1038/s41598-018-22222-y. PubMed PMID: 29535392; PubMed Central PMCID: PMC5849696.
164. de Biase D, Torricelli F, Ragazzi M, Donati B, Khun E, Visani M, Acquaviva G, Pession A, Tallini G, Piana S, Ciarrocchi A. Not the same thing: metastatic PTCs have a different background than ATCs. *Endocr Connect*. 2018 Nov 1. pii: EC-18-0386.R2. doi: 10.1530/EC-18-0386. [Epub ahead of print] PubMed PMID: 30400028; PubMed Central PMCID: PMC6280609.
165. Xu B, Reznik E, Tuttle RM, Knauf J, Fagin JA, Katabi N, Dogan S, Aleynick N, Seshan V, Middha S, Enepekides D, Casadei GP, Solaroli E, Tallini G, Ghossein R, Ganly I. Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. *Endocrine*. 2019 Jan 28. doi: 10.1007/s12020-019-01848-6. [Epub ahead of print] PubMed PMID: 30689169.

Case Reports

166. Eisen R N, Tallini G. Metastatic dermatofibrosarcoma protuberans with fibrosarcomatous change in the absence of local recurrence. *Cancer*. 1993;72:462-468.

167. Tallini G, Price F V, Carcangiu M L. Epithelioid angiosarcoma arising in uterine leiomyomas. *American Journal of Clinical Pathology*. 1993;100:514-518.
168. Salloum E, Tallini G, Levy A, Cooper D L. Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. *Cancer Investigation*. 1996;14:527-533.
169. Dal Cin P, Wanschura S, Kazmierczak B, Tallini G, Dei Tos A, Bullerdieck J, Van Den Berghe I, Moerman P, Van den Berghe H. Amplification and expression of the HMGIC gene in a benign endometrial polyp. *Genes Chromosomes Cancer*. 1998;22:95-99.
170. Madsen JA, Tallini G, Glusac EJ, Salem R, Braverman I, Robert ME. Biliary tract obstruction secondary to mycosis fungoides: a case report. *Journal of Clinical Gastroenterology*. 1999;28:55-60.
171. Rose MG, Tallini G, Pollak J, Murren J. Malignant hypoglycemia associated with a large mesenchymal tumor: case report and review of the literature. *The cancer journal from Scientific American*. 1999;5: 48-51.
172. Jain D, Parkash V, Li M, Gill J, Crouch J, Howe G, Tallini G. EBV RNA detection and glandular differentiation in nasopharyngeal carcinoma: report of two cases. *Archives of Pathology and Laboratory Medicine*. 2000;124:1369-1372.
173. Wang S, Ernst LM, Smith BR, Tallini G, Howe JG, Crouch J, Cooper DL. Systemic *Tropheryma whipplei* infection associated with monoclonal B-cell proliferation: a *Helicobacter pylori*-type pathogenesis? *Archives of Pathology and Laboratory Medicine*. 2003;127:1619-1622.
174. Caria P, Dettori T, Frau DV, Di Oto E, Morandi L, Parmeggiani A, Tallini G*, Vanni R*. Simultaneous occurrence of PAX8-PPAR γ and RET-PTC3 rearrangements in a follicular variant of papillary thyroid carcinoma. *Am J Surg Pathol*. 2012;36:1415-1420.*share senior authorship
175. Visani M, de Biase D, Baccarini P, Fabbri C, Polifemo AM, Zanini N, Pession A, Tallini G. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells. *Int J Surg Pathol*. 2013 Dec;21(6):546-52. doi: 10.1177/1066896912475073. Epub 2013 Feb 19
176. Casadei GP, Bertarelli C, Giorgini E, Cremonini N, de Biase D, Tallini G. Ectopic Thyroid Tissue in the Adrenal Gland: Report of a Case. *Int J Surg Pathol*. 2014 Jul 3. pii: 1066896914541001.
177. Fiorino S, de Biase D, Fornelli A, Masetti M, Cuppini A, Bondi A, Tallini G, Jovine E, Pession A. Hepatitis B virus infection and pancreatic neuroendocrine tumor: a case report. *Pancreas*. 2015 Mar;44(2):341-2. doi: 10.1097/MPA.0000000000000268.
178. Genestreti G, de Biase D, Di Battista M, Cavallo G, Degli Esposti R, Visani M, Acquaviva G, Brand T, Pession A, Tallini G*, Brandes AA*. Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma. *Clin Lung Cancer*. 2017 May;18(3):e215-e217. doi:

10.1016/j.cllic.2017.01.003. Epub 2017 Jan 11. PubMed PMID: 28162944. *share senior authorship

179. Forti Parri SN, Bonfanti B, Cancellieri A, De Biase D, Trisolini R, Zoboli S, Bertolaccini L, Solli P, Tallini G. Molecular analysis driven video-assisted thoracic surgery resections in bilateral synchronous lung cancers: from the test tube to the operating room. *Ann Transl Med.* 2017 Oct;5(20):397. doi: 10.21037/atm.2017.07.41. Review. PubMed PMID: 29152497; PubMed Central PMCID: PMC5673775.

Letters To The Editor

180. Parham D M, Pinto A, Tallini G, Novak R W. Rhabdomyosarcoma mimicking acute leukemia. *Archives of Pathology and Laboratory Medicine.* 1998;122:1047.
181. Tallini G, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotype. *Clinical Cancer Research.* 1999;5:3724-3725.
182. Vanni R, Marras-Virdis S, Gerosa C, Lai ML, Tallini G. Cytogenetics of thyroid nodules in Hashimoto thyroiditis. *Cancer Genetic and Cytogenetic.* 2000;120:87-88.
183. Eusebi V, Tallini G, Rosai J. Nuclear alterations and RET/PTC activation. *American Journal of Surgical Pathology.* 2004;28:974-975.
184. Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J. Encapsulated Well-differentiated Follicular-patterned Thyroid Carcinomas Do Not Play a Significant Role in the Fatality Rates From Thyroid Carcinoma. *Am J Surg Pathol.* 2010;34: author reply 1560.
185. Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J. Encapsulated Well-differentiated Follicular-patterned Thyroid Carcinomas Do Not Play a Significant Role in the Fatality Rates From Thyroid Carcinoma. *Am J Surg Pathol.* 2011;35: author reply 314.
186. Piana S, Ragazzi M, Tallini G, de Biase D, Ciarrocchi A, Frasoldati A, Rosai J. Papillary thyroid microcarcinoma associated with metastasis and fatal outcome: is the microcarcinoma an incidental finding?—reply. *Hum Pathol.* 2013 Sep;44(9):1962-3. doi: 10.1016/j.humpath.2013.05.019.
187. Gandolfi G, de Biase D, Sancisi V, Ragazzi M, Acquaviva G, Pession A, Piana S, Tallini G, Ciarrocchi A. Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases. *Endocr Relat Cancer.* 2014 Oct;21(5):L23-6. doi: 10.1530/ERC-14-0361. Epub 2014 Aug 20.

Reviews and commentaries

188. Tallini G, Carcangiu M L, Rosai J. Oncocytic neoplasms of the thyroid gland. *Acta Pathologica Japonica.* 1992;42:305-315.

189. Tallini G. Oncociti e neoplasie a cellule oncocitiche. *Pathologica*. 1996;88:85-90.
190. Tallini G, Costa J. Unraveling the pathogenesis of thyroid tumors using transgenic mice. *Laboratory Investigation*. 1997;76:301-305.
191. Tallini G. Oncocytic tumors. *Virchows Archives A (Anat Pathol)*. 1998;433:5-12.
192. Tallini G and Dal Cin P. HMGI(Y) and HMGI-C dysregulation, a common occurrence in human tumors. *Advances in Anatomic Pathology*. 1999;6:237-246.
193. Tallini G and Asa S L. RET oncogene activation in papillary thyroid carcinoma. *Advances in Anatomic Pathology*. 2001;8:345-354.
194. Tallini G. Molecular Pathobiology Of Thyroid Neoplasms. *Endocrine Pathology*, 2002;13:271-288.
195. Tallini G, Brandao G. Assessment of RET/PTC oncogene activation in thyroid nodules utilizing laser microdissection followed by nested RT-PCR. *Methods Mol Biol*. 2005;293:103-111.
196. Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino' L, Cappuzzo F. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). *Reviews on recent clinical trials*. 2006;1:1-13.
197. Cappuzzo F, Finocchiaro G, Metro G, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L. Clinical experience with gefitinib: an update. *Crit Rev Oncol Hematol*. 2006;58:31-45.
198. Gasparre G, Bonora E, Tallini G, Romeo G. Molecular features of thyroid oncocytic tumors. *Mol Cell Endocrinol*. 2010;321:67-76.
199. Bonora E, Tallini G, Romeo G. Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. *J Oncol*. 2010;2010:385206. Epub 2010 Jun 10.
200. Tallini G, Gallo C. Fine-needle aspiration and intraoperative consultation in thyroid pathology: when and how? *Int J Surg Pathol*. 2011;19:141-144.
201. Tallini G. Poorly differentiated thyroid carcinoma. Are we there yet? *Endocr Pathol*. 2011;22:190-194.
202. de Biase D, Visani M, Pession A, Tallini G. Molecular diagnosis of carcinomas of the thyroid gland. *Front Biosci (Elite Ed)*. 2014 Jan 1;6:1-14.
203. Franceschi E, Ermani M, Bartolini S, Bartolotti M, Poggi R, Tallini G, Marucci G, Fioravanti A, Tosoni A, Agati R, Bacci A, Pozzati E, Morandi L, Balestrini D, Ghimenton

- C, Crisi G, Brandes AA. Post progression survival in glioblastoma: where are we? *J Neurooncol.* 2015 Jan;121(2):399-404. doi: 10.1007/s11060-014-1651-7. Epub 2014 Nov 1.
204. Brandes AA, Bartolotti M, Marucci G, Ghimenton C, Agati R, Fioravanti A, Mascarini M, Volpin L, Ammannati F, Masotto B, Gardiman MP, De Biase D, Tallini G, Crisi G, Bartolini S, Franceschi E. New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. *Crit Rev Oncol Hematol.* 2015 Jun;94(3):348-359. doi: 10.1016/j.critrevonc.2014.12.016.
205. Garcia-Rostan G, Tallini G, Salvatore G. Anaplastic thyroid carcinoma: molecular tools for diagnosis and therapy. *Int J Endocrinol.* 2015;2015:341725. doi: 10.1155/2015/341725. Epub 2015 Feb 9. PubMed PMID: 25802520; PubMed Central PMCID: PMC4329788.
206. Visani M, Acquaviva G, Fiorino S, Bacchi Reggiani ML, Masetti M, Franceschi E, Fornelli A, Jovine E, Fabbri C, Brandes AA, Tallini G, Pession A, de Biase D. Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. *J Clin Pathol.* 2015 Nov;68(11):859-69. doi: 10.1136/jclinpath-2015-203246. Epub 2015 Aug 27. Review. PubMed PMID: 26314585.
207. Tallini G, Tuttle RM, Ghossein RA. The History of the Follicular Variant of Papillary Thyroid Carcinoma. *J Clin Endocrinol Metab.* 2017 Jan 1;102(1):15-22. doi: 10.1210/jc.2016-2976. PubMed PMID: 27732333.
208. Xu B, Tallini G, Ghossein RA. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Historical Context, Diagnosis, and Future Challenges. *Endocr Pathol.* 2017 Jun;28(2):128-138. doi: 10.1007/s12022-017-9478-3. Review. PubMed PMID: 28361392.
209. Fabbri C, Gibiino G, Fornelli A, Cennamo V, Grifoni D, Visani M, Acquaviva G, Fassan M, Fiorino S, Giovanelli S, Bassi M, Gherzi S, Tallini G, Jovine E, Gasbarrini A, de Biase D. Team work and cytopathology molecular diagnosis of solid pancreatic lesions. *Dig Endosc.* 2017 Sep;29(6):657-666. doi: 10.1111/den.12845. Epub 2017 Mar 16. Review. PubMed PMID: 28190274.
210. Seethala RR, Baloch ZW, Barletta JA, Khanafshar E, Mete O, Sadow PM, LiVolsi VA, Nikiforov YE, Tallini G, Thompson LD. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists. *Mod Pathol.* 2018 Jan;31(1):39-55. doi: 10.1038/modpathol.2017.130. Epub 2017 Oct 20. Review. PubMed PMID: 29052599.
211. Acquaviva G, Visani M, Repaci A, Rhoden KJ, de Biase D, Pession A, Tallini G. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. *Histopathology.* 2018 Jan;72(1):6-31. doi: 10.1111/his.13380. Review. PubMed PMID: 29239040.
212. de Biase D, Visani M, Acquaviva G, Fornelli A, Masetti M, Fabbri C, Pession A, Tallini G. The Role of Next-Generation Sequencing in the Cytologic Diagnosis of Pancreatic Lesions. *Arch Pathol Lab Med.* 2018 Apr;142(4):458-464. doi: 10.5858/arpa.2017-0215-RA. PubMed PMID: 29565213.

213. Franceschi E, Lamberti G, Visani M, Paccapelo A, Mura A, Tallini G, Pession A, De Biase D, Minichillo S, Tosoni A, Di Battista M, Cubeddu A, Bartolini S, Brandes AA. Temozolomide rechallenge in recurrent glioblastoma: when is it useful? *Future Oncol.* 2018 May;14(11):1063-1069. doi: 10.2217/fon-2017-0681. Epub 2018 May 9. PubMed PMID: 29741106.
214. Vasuri F, Visani M, Acquaviva G, Brand T, Fiorentino M, Pession A, Tallini G, D'Errico A, de Biase D. Role of microRNAs in the main molecular pathways of hepatocellular carcinoma. *World J Gastroenterol.* 2018 Jul 7;24(25):2647-2660. doi: 10.3748/wjg.v24.i25.2647. Review. PubMed PMID: 29991871; PubMed Central PMCID: PMC6034147.
215. Franceschi E, Mura A, De Biase D, Tallini G, Pession A, Foschini MP, Danieli D, Pizzolitto S, Zunarelli E, Lanza G, Bartolini D, Silini EM, Visani M, Di Oto E, Tosoni A, Minichillo S, Lamberti G, Lanese A, Paccapelo A, Bartolini S, Brandes AA. The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival? *Future Oncol.* 2018 Jul;14(16):1559-1567. doi: 10.2217/fon-2017-0634. Epub 2018 Jun 25. PubMed PMID: 29938525.
216. Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. *Mod Pathol.* 2018 Dec;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y. Epub 2018 Aug 23. PubMed PMID: 30140036; PubMed Central PMCID: PMC6265262.

Books and book chapters

217. Tallini G, Rosai J. Angiosarcomas, in D. J. Demis in *Clinical Dermatology*. Lippincott-Raven, Philadelphia-New York, 22nd revision, 1995;2:Unit 7-71(1-6).
218. Tallini G, Rosai J. Hemangioendotheliomas and other unusual vascular tumors, in D. J. Demis in *Clinical Dermatology*. Lippincott-Raven, Philadelphia-New York, 22nd revision, 1995;2:Unit 7-71A(1-11).
219. Tallini G. Recent advances in surgical pathology: cytogenetics and molecular alterations in soft tissue tumors. In: *Surgical Pathology Update 2001*. S Hauptmann, M Dietel, M Sobrinho-Simoes, editors. ABW Wissenschaftsverlag GmbH, Berlin, Germany, 2001;506-511.
220. Fadare O, Tallini G. Thyroid: anaplastic (undifferentiated) carcinoma. *Atlas Genet Cytogenet Oncol Haematol.* June 2003 .
URL:<http://www.infobiogen.fr/services/chromcancer/Tumors/AnaCarciThyroidID5069.html>
221. Fadare O, Tallini G. Thyroid: oncocytic tumors. *Atlas Genet Cytogenet Oncol Haematol.* June 2003.
URL:<http://www.infobiogen.fr/services/chromcancer/Tumors/OncocytThyroidID5068.html>

222. Sobrinho Simoes M, Albores-Saavedra J, Tallini G, Santoro M, Volante M, Pilotti S, Carcangiu ML, Papotti M, Matias-Guiu X, Guiter GE, Zakowski M, Sakamoto A. Poorly differentiated thyroid carcinoma in World Health Organization Classification of Tumors-Pathology and Genetics, Tumors of Endocrine Organs, IARC Press, Lyon (France), 2004, pp.73-76.
223. Ordonez N, Baloch Z, Matias-Guiu X, Evans H, Farid NR, Fagin JA, Kitamura Y, Tallini G, Eng C, Haigh PI, Faquin WC, Sugitani I, Giuffrida D, Boerner S. Undifferentiated (Anaplastic) thyroid carcinoma in World Health Organization Classification of Tumors-Pathology and Genetics, Tumors of Endocrine Organs, IARC Press, Lyon (France), 2004, pp.77-80.
224. Tallini G, Brandao G. Assessment of RET/PTC oncogene activation in thyroid nodules utilizing laser microdissection followed by nested RT-PCR in Laser Capture Microdissection Methods and Protocols, Murray GI and Curran S Editors. Humana Press, Totowa NJ, 2005; chapter 9, pp.103-111.
225. Tallini G, Hui P. Sarcomas (Section III-Solid tumors, Chapter 26) in Molecular Pathology in Clinical Practice, edited by Debra Leonard. Springer Science+Buisness Media, 2007, pp.287-297.
226. de Biase D, Morandi L, Tallini G. NCOA4 (Nuclear Receptor Coactivator 4, a.k.a. ELE1, RFG, PTC3). Atlas Genet Cytogenet Oncol Haematol. October 2008.
URL:<http://AtlasGeneticsOncology.org/Genes/NCOA4ID218ch10q11.html>
227. de Biase D, Morandi L, Tallini G. PAX8 (Paired Box Protein PAX8). Atlas Genet Cytogenet Oncol Haematol. July 2009.
URL:<http://AtlasGeneticsOncology.org/Genes/PAX8ID382ch2q13.html>
228. Eusebi V (curatore), Faa G, Franco V, Maiorano E, Palombini L, Papotti M, Sapino A, Tallini G. (2010). Robbins e Cotran: Le basi patologiche delle malattie (Italian translation of Robbins and Cotran Pathologic basis of disease), 8th edition, Elsevier, Milano, 2010. ISBN: 978-1-4160-3121-5.
229. Rosai J, Tallini G. The thyroid gland, in Rosai and Ackerman's Surgical Pathology 10th edition. Mosby Elsevier, New York 2011, pp 487-564. ISBN: 9780323069694
230. Cremonini N., Tallini G. Crescenzi A. Esami Genetici. Manuale per la Valutazione e l'inquadramento delle Patologie della Tiroide. Associazione Medici Endocrinologi, Attanasio R, Borretta G, Buonomo L, Cremonini N, Dorizzi R, Papini E, Toscano V Editors. Scripta S.C., Verona 2011. pp 215-224.
231. Rosai J, DeLellis RA, Carcangiu ML, Frabel WJ, Tallini G (Editors). Tumors of the Thyroid and Parathyroid Glands. AFIP Atlas of Tumor pathology, Fourth series, Fascicle 21. American Registry of Pathology, Silver Spring, Maryland USA, 2014.
232. Tallini G, De Biase D, Hui P. Sarcomas and Related Mesenchymal Tumors (Section III-Solid tumors, Chapter 37) in Molecular Pathology in Clinical Practice, edited by Debra

- Leonard. Springer Science+Buisness Media, 2016, pp.487-506. DOI 10.1007/978-3-319-19674-9. ISBN 978-3-319-19674-9.
233. Chan JKC, Nikiforov YE, Tallini G. Introduction - Other encapsulated follicular-patterned thyroid tumours. World Health Organization Classification of Tumours of Endocrine Organs. Lloyd RV, Osamura RY, Klöppel G, Rosai J editors. WHO/IARC Classification of Tumours, 4th Edition, Volume 10. IARC: Lyon (France), 2017, pp.75-76. ISBN-13 (Print Book): 978-92-832-4493-6.
234. Chan JKC, Tallini G. Tumours of uncertain malignant potential - Other encapsulated follicular-patterned thyroid tumours. World Health Organization Classification of Tumours of Endocrine Organs. Lloyd RV, Osamura RY, Klöppel G, Rosai J editors. WHO/IARC Classification of Tumours, 4th Edition, Volume 10. IARC: Lyon (France), 2017, pp.76-77. ISBN-13 (Print Book): 978-92-832-4493-6.
235. Nikiforov YE, Ghossein RA, Kakudo K, LiVolsi V, Papotti M, Randolph GW, Tallini G, Thompson LDR, Tuttle RM. Non-invasive follicular thyroid neoplasm with papillary-like nuclear features - Other encapsulated follicular-patterned thyroid tumours. World Health Organization Classification of Tumours of Endocrine Organs. Lloyd RV, Osamura RY, Klöppel G, Rosai J editors. WHO/IARC Classification of Tumours, 4th Edition, Volume 10. IARC: Lyon (France), 2017, pp.78-80. ISBN-13 (Print Book): 978-92-832-4493-6.
236. LiVolsi V, Abdulkader I, Baloch ZW, Bartolazzi A, Chan JKC, De Lellis RA, El-Naggar AK, Eloy C, Eng C, Fagin JA, Ghossein RA, Giordano TJ, Kondo T, Lloyd RV, Mete O, Nikiforov YE, Nonaka D, Paschke R, Perren A, Rosai J, Sadow P, Schneider AB, Sobrinho-Simoes M, Tallini G, Williams MD. Follicular thyroid carcinoma. World Health Organization Classification of Tumours of Endocrine Organs. Lloyd RV, Osamura RY, Klöppel G, Rosai J editors. WHO/IARC Classification of Tumours, 4th Edition, Volume 10. IARC: Lyon (France), 2017, pp. 92-95. ISBN-13 (Print Book): 978-92-832-4493-6.
237. LiVolsi V, Baloch ZW, Sobrinho-Simoes M, Tallini G. Hürthle (oncocytic) cell tumours. World Health Organization Classification of Tumours of Endocrine Organs. Lloyd RV, Osamura RY, Klöppel G, Rosai J editors. WHO/IARC Classification of Tumours, 4th Edition, Volume 10. IARC: Lyon (France), 2017, pp. 96-99. ISBN-13 (Print Book): 978-92-832-4493-6.
238. Tallini G, Asioli S, Aubert S, Carcangiu ML, Chernock R, Fellegara G, Ghossein RA, Kakudo K, LiVolsi V, Lloyd RV, Matias-Guiu X, Nikiforov YE, Papotti M, Perren A, Rosai J, Sobrinho-Simoes M. Poorly differentiated thyroid carcinoma. World Health Organization Classification of Tumours of Endocrine Organs. Lloyd RV, Osamura RY, Klöppel G, Rosai J editors. WHO/IARC Classification of Tumours, 4th Edition, Volume 10. IARC: Lyon (France), 2017, pp. 100-103. ISBN-13 (Print Book): 978-92-832-4493-6.
239. El-Naggar AK, Baloch ZW, Eng C, Evans HL, Fagin JA, Faquin W, Fellegara G, Franssila KO, Giuffrida D, Katoh R, Kebebew E, Kondo T, Matias-Guiu X, Nikiforov YE, Papotti M, Smallridge R, Sugitani I, Tallini G, Wakely PE, Westra W, Wick MR, Williams MD. Anaplastic thyroid carcinoma. World Health Organization Classification of Tumours of Endocrine Organs. Lloyd RV, Osamura RY, Klöppel G, Rosai J editors. WHO/IARC

Classification of Tumours, 4th Edition, Volume 10. IARC: Lyon (France), 2017, pp. 104-106. ISBN-13 (Print Book): 978-92-832-4493-6.

240. Tallini G and Giordano TJ. Thyroid Gland, in Rosai and Ackerman's Surgical Pathology 11th edition, by Goldblum, Lamps, McKenney and Myers. Elsevier, 2018, pp 278-354. ISBN: 978-0-323-26339-9.